Cost benefit of sumatriptan to an employer

Journal of Occupational and Environmental Medicine

Volumn 39, Issue 7, 1997, Pages 652-657

  Legg, Randall F ^a   Sclar, David A ^a,b   Nemec, Neil L ^a   Tarnai, John ^b   Mackowiak, John I ^c  

^a Qual Med Health Plan of Washington Inc   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c Center for Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN;

ABSENTEEISM; ARTICLE; COST BENEFIT ANALYSIS; EMPLOYEE; EMPLOYER; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; OCCUPATIONAL HEALTH; PRODUCTIVITY;

ABSENTEEISM; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; INTERVIEWS; MIGRAINE DISORDERS; OCCUPATIONAL HEALTH; OUTCOME ASSESSMENT (HEALTH CARE); SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0030805079     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043764-199707000-00010     Document Type: Article

References (14)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. JAMA. 1992; 267:64-69.
2. Lipton RB, Stewart WF, Celentano DD, et al. Undiagnosed migraine headaches: a comparison of symptom based and reported physician diagnosis. Arch Intern Med. 1992;152:1273-1278.
3. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother. 1994;28:659-664.
4. Streator SE, Shearer SW. Pharmacoeconomic impact of injectable sumatriptan on migraine associated healthcare costs. Am J Managed Care. 1996;2:67-76.
5. Greiner DL, Addy SN. Sumatriptan use in a large group-model health maintenance organization. Am J Health Syst Pharm. 1996;53:633-638.
6. Koopmanschap MA, Rutten F. Indirect costs in economic studies: confronting the confusion. PharmacoEconomics. 1993;4:446-454.
7. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982;60: 429-462.
8. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine in the US. PharmacoEconomics. 1992;2:67-76.
9. Rice DP. Estimating the Cost of Illness. [Health Economics Series No. 6, Public Health Service.] Washington, DC: US Government Printing Office; 1966;20-39.
10. Peeples PJ, Wertheimer AI, Mackowiak JM, McGhan WF. Controversies in measuring and valuing indirect costs of productivity foregone in a cost of illness evaluation. J Res Pharmaceutical Economics. 1997, in press.
11. Peeples PJ, Wertheimer AI, Mackowiak JM, McGhan WF. Assessment and measurement of worker productivity [Part 2 of 2.] J Res Pharmaceutical Econ. 1997, in press.
12. US Bureau of Labor Statistics. Occupational Wage Rates. [Bulletin 2307, #665.] Washington, DC: US Government Printing Office; 1993.
13. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University; 1986.
14. Legg RF, Sclar D, Nemec NL, Tarnai J, Mackowiak JI. Cost-effectiveness of sumatriptan in a managed care population. Am J Managed Care. 1997;3:117-122.